Compare Charles River Laboratories Intl. Inc (CRL) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Omnicom Group Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Omnicom Group Inc. trades at $85.75 (market cap $23.58B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 3.72% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | OMC | |
|---|---|---|
Market Cap | $13.46B | $23.58B |
Sector | Health | Media |
52-Week High | $282.00 | $86.22 |
52-Week Low | $145.57 | $67.27 |
Enterprise Value | $16.30B | $31.66B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Omnicom Group (OMC) trades at $85.45, up 0.95% with a bullish technical outlook and strong institutional support. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Recent acquisition of Interpublic Group has driven 6.1% organic revenue growth and margin expansion, though 2025 saw a net loss of $54.5 million. Analyst consensus price target stands at $107 with 32% buy ratings.
OMC presents a value opportunity with attractive valuation metrics (P/S 0.97) and 4% dividend yield, supported by post-merger synergies and strong cash flow generation. Key risks include integration challenges from the Interpublic acquisition, competitive pressures in advertising services, and debt levels following the merger. The stock's current price offers 25% upside to consensus targets with institutional accumulation signaling confidence in the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
